• Citer

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

par Cornely, Oliver A;Crook, Derrick W;Esposito, Roberto;Poirier, André;Somero, Michael S;Weiss, Karl;Sears, Pamela;Gorbach, Sherwood L;Jacobs, Frédérique
Référence Lancet. Infectious diseases, 12, 4, page (281-289)
Publication Publié, 2012-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Auteur:	Cornely, Oliver A; Crook, Derrick W; Esposito, Roberto; Poirier, André; Somero, Michael S; Weiss, Karl; Sears, Pamela; Gorbach, Sherwood L; Jacobs, Frédérique
Informations sur la publication:	Lancet. Infectious diseases, 12, 4, page (281-289)
Statut de publication:	Publié, 2012-04
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Aged
	Aminoglycosides -- therapeutic use
	Anti-Bacterial Agents -- therapeutic use
	Clostridium difficile -- isolation & purification
	Diarrhea -- drug therapy -- microbiology
	Double-Blind Method
	Enterocolitis, Pseudomembranous -- drug therapy -- microbiology
	Feces -- microbiology
	Female
	Humans
	Kaplan-Meier Estimate
	Male
	Middle Aged
	Prospective Studies
	Vancomycin -- therapeutic use
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	OPT-80-004 Clinical Study Group
Langue:	Anglais
Identificateurs:	urn:issn:1473-3099
	info:doi/10.1016/S1473-3099(11)70374-7
	info:pii/S1473-3099(11)70374-7
	info:pmid/22321770